AMANAT

We are asked to evaluate AMANAT (Amanat Holdings PJSC) from the RISK lens perspective. We need to check the concrete breaks: ocf_to_ni < 0.7, net_debt_to_ebitda > 4, ebitda_interest_cover < 2, liquidity.advv_30d_aed_m < 1, quarterly_gaps present, dividend cut evident in financial_statements. Score each break only when the cited figure crosses the threshold. Let's examine the pack data: 1. ocf_to_ni: financial_statements.derived.ocf_to_ni = 0.87. This is not <0.7, so no break. 2. net_debt_to_ebitda: We need to calculate net debt and EBITDA. Net debt = total debt - cash. We have total_liabilities? Actually, debt might be approximated by interest-bearing debt, but we are given interest_expense = -30.3 (annual 2025). We don't have explicit total debt. But we can compute net debt from balance sheet? The pack doesn't provide a "net debt" field directly. However, we can estimate: total liabilities = 1129.7, cash = 1450.4, so net cash is positive (cash > total liabilities). But not all liabilities are debt. More appropriately, we might use debt-to-equity ratio given: fundamentals.debt_to_equity = 0.2149. That implies total debt = 0.2149 * equity (3448.4) = ~741.2. Net debt = 741.2 - 1450.4 = -709.2 (net cash). EBITDA: operating income + depreciation. We have operating income = 275.5, but depreciation not given. However, we can approximate EBITDA as operating income + depreciation. Since we don't have depreciation, we might use operating income as a proxy, but that would be EBIT, not EBITDA. The threshold says net_debt_to_ebitda > 4. With net cash, ratio is negative, so definitely not >4. No break. 3. ebitda_interest_cover < 2: EBITDA/interest_expense. Interest expense = 30.3 (note: it's negative in data, but we take absolute value). EBITDA we need. Without depreciation, we might assume it's at least operating income of 275.5, so 275.5/30.3 = 9.09, which is >2. So no break. 4. liquidity.advv_30d_aed_m < 1: advv_30d_aed_m = 2.6368. This is >1, so no break. 5. quarterly_gaps present: financial_statements.quarterly_gaps = ["no quarter between 2025-03-31 and 2025-09-30"]. So there is a quarterly gap (missing Q2 2025). This is a break. 6. dividend cut evident: Look at dividends paid history. financial_statements.annual.0.dividends_paid = -18.5 (2025), previous year -15.8 (2024), -100.0 (2023), -150.0 (2022). Over years, dividends have varied. But looking at recent trend, 2024: -15.8, 2025: -18.5, so dividends increased slightly. However, check if there was a cut from the dividend per share? corporate_actions history: 2026: 7% cash dividends, 2025: 1.6%, 2024: 3%, 2023: 4%, 2022: 6%. The 2025 dividend (paid in 2025? ex_date 2025-04-25, details 1.6% cash dividends) seems lower than 2024's 3%. But careful: 2025 ex_date corresponds to dividend declared for which year? Usually, dividends are paid after year-end. The 2025 dividend paid in April 2025 likely relates to 2024 earnings. The 2024 dividend ex_date 2024-09-27, details 3% cash dividends, probably for 2023. So the most recent dividend is 2026: ex_date 2026-04-09, 7% cash dividends. That's an increase. The 1.6% in 2025 is a cut from 3% in 2024? Actually, we need to look at the amounts. The financial_statements annual dividends_paid: 2025: -18.5, 2024: -15.8, so cash amount increased. The percentage yield is based on share price. But the threshold says "dividend cut evident in financial_statements". If we look at the annual dividends_paid, it went from 15.8 to 18.5, not a cut. The corporate actions show varying percentages, but the 1.6% might be a special or different. However, the most recent annual dividends paid figure (2025) is higher than 2024, so no cut evident. Thus, no break. So we have only 1 break: quarterly_gaps present. According to rules: 1 break -> HOLD unless offset. There's no offsetting condition specified. So stance is HOLD. Now we need to output JSON with citations, point, risk, stance, confidence, target. We need to cite exact figures. For the break, we must cite the field: financial_statements.quarterly_gaps.0, value: "no quarter between 2025-03-31 and 2025-09-30". Also, we may want to cite the ocf_to_ni and others to show they don't break. But the instructions say: "citations: list the exact pack fields your case rests on ... non-HOLD stances need at least 2." Since our stance is HOLD, we might need only one? But we should include all breaks we identified. The instructions say: "Never assign SELL without naming which thresholds tripped, with the cited figures, one lens..." For HOLD due to one break, we should cite that break. Also, we need to provide evidence that the other thresholds didn't trip? Possibly not required, but to support our reasoning, we might include the ocf_to_ni to show cash conversion is okay. But strictly, the citations should be the fields our case rests on. The case for HOLD rests on the quarterly gap. So we can cite that. Also, we could cite the ocf_to_ni, etc., but not necessary. The instruction: "non-HOLD stances need at least 2" so for HOLD, one citation is allowed. But to be thorough, I'll include the key break and maybe one other to show strength elsewhere? However, the example output includes multiple citations even for HOLD? Not specified. I think we should list all breaks we checked and the result. But the output must be a JSON object with keys in order. Let's decide: one citation for the break. Confidence: Since we have 1 break, what confidence band? 50-69 = clear evidence with real conflicts? The break is a real conflict (quarterly gap indicates unverifiable trend), but other metrics are clean. So I'd say confidence around 60-70? We'll pick 65. But we need to consider the horizon: 4 weeks. The gap is a historical data issue, not necessarily a near-term catalyst. The recent news about full acquisition of Cambridge Health Group (June 20) might be positive. However, the quarterly gap is a data quality concern. I'll set confidence to 65, as there is clear evidence with conflicts. Target: We are asked to derive a target from pack evidence for the 4-week horizon, not restate analyst target. We can derive based on technicals or fundamentals? We might not have a clear target. Since it's HOLD, we can output null or no target? The key allows null. The instruction: "If you output a target, derive it from pack evidence for the 4-week horizon". We can attempt to derive a short-term price target. But with a HOLD, we might not provide a target. I'll output null. Risk: "one line" - succinct risk statement. Something like: "Quarterly reporting gap introduces uncertainty in trend continuity." Point: "one sentence citing a figure" - e.g., "Operating cash flow covers net income at 0.87x, but a missing Q2 2025 filing weakens earnings verifiability." Stance: "HOLD" Now, format: {"citations":[{"field":"financial_statements.quarterly_gaps.0","value":"no quarter between 2025-03-31 and 2025-09-30"}],"point":"...","risk":"...","stance":"HOLD","confidence":65,"target":null} Let's finalize the point and risk. Point: "OCF/NI of 0.87x supports cash conversion, but the absence of a Q2 2025 quarterly filing creates a trend gap." Risk: "Missing quarterly data undermines short-term earnings trajectory confidence." Confidence: 65 (fits 50-69 range: clear evidence with real conflicts). Target: null I'll output JSON.

We are asked to provide a MACRO-LIQUIDITY lens stance on AMANAT. The peg and Fed rate are identical for all DFM names, so they cannot by themselves justify a stance on this one. We need to cite which of this name's own figures makes it MORE or LESS exposed to the macro backdrop than the market. The figures to consider: fundamentals.debt_to_equity (rate sensitivity), tv_technicals.beta_1y, liquidity.advv_30d_aed_m (flow sensitivity), sector, peer_context percentiles. We must cite macro.fed_funds_rate / macro.vix / macro.yield_curve_2s10s_pct for the backdrop AND the differentiating name-level figure. Weigh uae_macro_news where present. The stance covers 4-week horizon ending 2026-08-17. Today is 2026-07-20. We need to output a JSON with keys: citations, point, risk, stance, confidence, target. First, let's extract relevant figures from the pack: - fundamentals.debt_to_equity: 0.2149 (low, indicating low rate sensitivity? Actually, debt to equity is 21.49%, relatively low, but we need to compare to market or sector? The lens says to use it as a differentiating figure. Low debt means less sensitivity to interest rate changes. But the macro backdrop: fed_funds_rate: 3.63, us_10y_yield: 4.57, yield curve slightly positive 0.37%. VIX 16.73. The peg is stable. Amanat being a financial services company in Dubai, low debt to equity might make it less exposed to rising rates? But rates are actually moderate and the yield curve is slightly positive. However, the low debt to equity is a positive in a tightening or uncertain environment. We need to see how it compares to peers? The peer context doesn't give median debt to equity. But we can use the percentile of something? The lens says cite peer_context percentiles, but only pe_percentile and div_yield_percentile are given. So we might use those indirectly? Actually, the instruction says "Cite macro.fed_funds_rate / macro.vix / macro.yield_curve_2s10s_pct for the backdrop AND the differentiating name-level figure; weigh uae_macro_news where present". So we need to pick a name-level figure that differentiates its macro sensitivity. - tv_technicals.beta_1y: 0.4226. Beta is low, indicating it's less volatile than the market. That could mean it's less sensitive to macro swings, more defensive. - liquidity.advv_30d_aed_m: 2.6368 million AED. This is relatively low? Need to compare to other stocks? But without distribution, we can say it's low liquidity, which might make it more sensitive to flow shocks. But the lens is macro-liquidity, so low liquidity could be a risk factor, but not necessarily a positive. - sector: Financial Services. The macro backdrop might affect financials differently. With a positively sloped yield curve, financials might benefit from net interest margins? But Amanat is a holding company with healthcare and education investments, not a traditional bank. So sector might have limited direct impact. - peer_context: pe_percentile 64, meaning it trades at a higher PE than 64% of peers. That might make it more expensive and thus more sensitive to macro shocks? But the lens is about macro exposure, not valuation pressure. - We also have uae_macro_news: several articles, including "UAE private-sector Emiratization surpasses 190,000...", "Jaywan Debuts As UAE's First National Payment Scheme", "Houthis declare naval embargo against Saudi Arabia". The last one could be negative for regional stability, potentially affecting UAE markets. But Amanat's low beta might insulate it. Given the macro backdrop: Fed rate 3.63% is moderate; the yield curve is barely positive at 0.37%, not strongly inverted, which is less threatening for financials. VIX at 16.73 is relatively calm. So the macro environment is not extremely risky, which might favor holding. However, with a 4-week horizon, we need to see if there's a catalyst. The last results filing was May 14, 2026 (Q1 2026). The next earnings are probably not within the 4-week horizon (next quarter ends Sept 30, so filing might be in November). So no immediate catalyst from earnings. The recent news includes completion of Cambridge Health Group acquisition in June 2026, and a strategic partnership on July 6. Those might be positive, but not necessarily a strong catalyst for a short-term move. We must choose a stance: BUY, SELL, or HOLD. Since the macro lens doesn't strongly point to a buy or sell based on the provided data, and the evidence might be mixed, a HOLD stance might be appropriate. But the instructions say: "A non-HOLD stance must cite which of this name's own figures makes it MORE or LESS exposed to the macro backdrop than the market." So if we go HOLD, we don't necessarily need to cite differentiating figures? Actually, the instruction: "A non-HOLD stance must cite which of this name's own figures makes it MORE or LESS exposed to the macro backdrop than the market." That implies that for HOLD, we might not need to cite differentiating figures, but the overall output still requires citations. So HOLD is acceptable if the evidence is not compelling. But we need to see if there is a bullish or bearish tilt. The low beta and low debt suggest defensive characteristics, which might be favorable if macro uncertainty rises. However, the VIX is low and yield curve positive, so macro uncertainty is not high. So the defensive nature doesn't provide an edge. Low liquidity might be a concern if there's a market sell-off. The stock has outperformed the DFMGI: ret_3m_pct 15.99% vs dfmgi_ret_3m_pct -1.19%. That might suggest it has already run up and could be overbought? But RSI14 is 48.4, neutral. The recent news about CHG acquisition might already be priced in. Given the lack of a strong catalyst within 4 weeks and mixed signals, HOLD seems reasonable. We need to provide a point, risk, confidence, target. Confidence bands: 90-100 needs multiple independent cited figures align AND a dated catalyst inside horizon. We don't have a dated catalyst, so max 70-89 if several aligned figures but no catalyst. Here, maybe a few aligning: low beta, low debt, stable macro, but no catalyst. So confidence could be around 60-70? Actually, 70-89 says "several aligned cited figures, no dated catalyst". We might have low beta and low debt aligning to suggest defensive quality, but macro backdrop is calm, so not necessarily a benefit. So maybe confidence around 50-69: "clear evidence with real conflicts". There is conflict: low beta defensive vs. low liquidity risk. The macro is calm, so defensive not needed. So confidence maybe 55. But higher confidence would require solid evidence. Target: We can derive a target from the evidence for the 4-week horizon. The analyst target mean is 1.445, which is a 12-month target, we should not restate that. For a 4-week horizon, we might base on technicals or a modest drift. With no strong direction, a target near current price may be appropriate. Current spot is 1.34. We could set target as null if we have no basis, but the instruction says "output a target, derive it from pack evidence for the 4-week horizon". Maybe we can use the implied upside from analyst but that's 12-month. No short-term target available. So target might be null. Given the macro-liquidity lens, we could argue that the low beta and low debt make it a safe haven, but no catalyst. So HOLD with confidence around 50-60. Let's cite: macro.fed_funds_rate 3.63, macro.vix 16.73, fundamentals.debt_to_equity 0.2149, tv_technicals.beta_1y 0.4226, liquidity.advv_30d_aed_m 2.6368. Also, yield curve 0.37%. For point: "Low debt/equity (0.21) and 1Y beta (0.42) reduce macro sensitivity vs. peers, but thin ADV (AED2.6m) raises flow risk; calm VIX (16.73) and stable peg limit urgency." Risk: "A regional shock (Houthi embargo) could spark risk-off flows, hurting low-liquidity names." Stance: HOLD. Confidence: 55. Target: null. Check: citations must be list of objects with field and value. We'll include 4-5 citations. Point must be one sentence citing a figure. Risk one line. All good. We'll output JSON only.

We are asked to provide a JSON output for AMANAT as the SECTOR specialist, focusing on business economics, growth, margins, leverage, dividend durability. The stance covers the 4-week horizon ending 2026-08-17. We need to reason over the evidence pack and output only JSON with keys: citations, point, risk, stance, confidence, target. First, understand the sector: Financial Services. But AMANAT is a healthcare and education investment company. The sector news provided is mostly banking and fintech, not directly aligned. However, our lens is sector specialist, so we consider sector trends and fundamentals. Let's analyze the financial statements trends: - Revenue: annual 2025: 931.7, 2024: 796.1, 2023: 718.1, 2022: 513.1. Growth: 17.8% yoy in 2025 per fundamentals.rev_growth_yoy: 17.7932. CAGR over 2 years (2023-2025) is derived rev_cagr_2y_pct: 13.9%. So revenue growth is solid. - Gross margin: 2025: 43.1%, 2024: 44.5%, 2023: 45.7%, 2022: 44.8%. Slight decline but still healthy. - Operating margin: 2025: 29.6% (op_margin_pct in annual: 29.6), up from 26.4% in 2024, and 13.4% in 2023. Big improvement. - Net margin: 2025: 22.3% (net_margin_pct: 22.3), up from 16.8% in 2024. fundamentals.net_margin: 20.9093 (TTM? maybe as of latest quarter? but annual 2025 is 22.3). Net income: 208.1 in 2025 vs 133.8 in 2024, huge growth. eps_growth_yoy: 96.0177% — but note, this might be from low base because 2023 had net loss. - Quarterly: latest quarter Q1 2026: revenue 298.5, net income 72.1, op income 77.5, net margin 24.2%, revenue yoy +24%. This follows Q4 2025 (derived) revenue 309.6, net 82.7, margin 26.7%. So margins are expanding. - Interest expense: 2025: -30.3, down from -36.0 in 2024, despite higher debt? total liabilities 1129.7 vs 1090.2, so slight increase. Debt to equity: 0.2149 (fundamentals), liabilities to equity: 0.33 (annual). Low leverage. - Cash: huge cash balance: 1450.4 in 2025, up from 503.0 in 2024. So liquidity is very strong. OCF: 180.8, FCF: 90.8. Dividends paid: -18.5? That seems low. Wait, dividends_paid in annual 2025 is -18.5, but corporate actions show 7% cash dividends in 2026 ex-date April 2026. The financial statement dividends_paid likely only reflects actual cash outflow? In 2025, they paid -18.5, but in 2024 they paid -15.8, and in 2023 -100.0. The payout ratio is 77.85% (fundamentals). Dividend yield: 5.1471% (fundamentals). So they pay high dividends. FCF 90.8, dividends paid 18.5, so dividend covered by FCF (derived div_paid_to_fcf: 0.2, meaning dividends are only 20% of FCF? Actually derived: div_paid_to_fcf: 0.2, which suggests dividends paid / FCF = 0.2? That would mean dividends 18.5 / 90.8 = 0.203. So dividend coverage is very strong. But payout ratio is 77.85%? Payout ratio is dividends / net income? Net income 208.1, 77.85% would be 162.0, but dividends paid are only 18.5? Something inconsistent. Possibly dividends paid in the cash flow statement only reflects cash dividends during the year, and the payout ratio is based on declared dividends? The corporate actions show 7% cash dividends in 2026, but that's for the year 2025? Ex-date April 2026, so that dividend relates to 2025 earnings. In 2025, they had a 1.6% dividend ex-date April 2025. So maybe the -18.5 reflects the cash paid for dividends during 2025, which might include prior year's final dividend? That can be confusing. But fundamentals.payout_ratio is 77.85, so that suggests of earnings they pay out 77.85%. However, the cash flow statement shows much lower dividends paid. This might be because they pay dividends from subsidiaries? Or maybe the fundamentals data is TTM and includes declared dividends? We need to check: dividends_paid in annual 2025: -18.5, but in 2024: -15.8, 2023: -100.0. That seems very low for a company with net income 208.1. Possibly the dividends paid line in the cash flow is only for the parent? In the filing context, there's no clear explanation. But the dividend yield is 5.1471%, which on market cap 3.34B AED gives annual dividend of about 171.7 million AED. That would align with a payout ratio of 77.85% on TTM net income? fundamentals.net_margin is 20.9093, but we don't have TTM net income figure. Net income 2025: 208.1, Q1 2026: 72.1, so TTM might be higher. 208.1 + 72.1 - 44.4 (Q1 2025) = 235.8? Actually TTM: Q1 2026 (72.1) + Q4 2025 (82.7) + Q3 2025 (32.2) + Q2 2025 (derived? We don't have Q2 2025, but FY2025 - Q1-Q3: 931.7 - 240.7 - 153.8 - ? Actually quarters: Q1 2025: 240.7, Q3 2025: 153.8, Q4 2025: 309.6, so Q2 2025 would be 931.7 - (240.7+153.8+309.6) = 227.6. Net income: Q1 2025: 44.4, Q3: 32.2, Q4: 82.7, Q2: ? FY2025 net: 208.1, so Q2 net = 208.1 - 44.4 - 32.2 - 82.7 = 48.8. Then TTM net (ending Q1 2026) = 72.1 + 82.7 + 32.2 + 48.8 = 235.8. Payout ratio 77.85% implies dividends of 183.6 million. That is close to the 171.7 million implied by yield. So the dividends_paid in the cash flow statement is likely only for the holding company and doesn't reflect total dividends paid to shareholders? There may be dividends from subsidiaries that are not shown. Regardless, the derived div_paid_to_fcf uses the -18.5 figure, which would be misleading. But we also have the dividend yield of 5.15% which is attractive and covered by earnings. - ROE: 8.1073% (fundamentals), which is moderate but improving. equity 3448.4, net income 208.1 gives 6.03% (derived roe_stmt_pct: 6.0). Slight difference. ROA: 5.0219%. Not high but acceptable for a holding company. - Valuation: PE TTM 15.12, PB 1.17, PS 3.42. Compared to peers: median PE 11.32, median PB 1.35, so Amanat trades at a premium on PE but discount on PB. PE percentile 64, meaning it's higher than 64% of peers. Dividend yield is 5.15%, peer median 4.55%, so above median. - Analyst: 2 analysts, rec none, target mean 1.445, implying upside 7.8%. No ratings changes (rating_drift 0, net_up_30d 0). Consensus signal drift shows tv_recommend_all -0.0909 (slightly bearish), and delta_5d -0.267, delta_10d -0.445, indicating recent bearish drift. Forward PE 22.33, which is high. - Technicals: spot 1.34, above ma200 (1.1924), above ma50 (1.3112). RSI 48.4 neutral. ret_1m +3.88%, ret_3m +15.99%, outperforming DFMGI by 10.8% over 3m. But DFMGI down 1.19% over 3m, so Amanat strongly outperformed. However, max drawdown 1y -16.4%. Volatility annual 16.9%. TV recommend all -0.1576, with CCI -115.76, stoch_k 31.1, williams_r -63.6, so some bearish signals. - Catalysts: last results filing was May 14, 2026 (Q1 2026). Next results likely not within the 4-week horizon (since Q2 would be due around August, but horizon ends Aug 17, Q2 report might be filed in August? The historical pattern: Q2 results: 2024 Q2? Actually filing dates: 2025-08-13 (that's Q2 2025?), 2025-11-12 (Q3), 2026-02-12 (Q4), 2026-05-14 (Q1). So Q2 is typically filed mid-August. Since horizon ends Aug 17, there might be a Q2 2026 filing within the horizon (possibly around Aug 13-14). The filing_context doesn't specify, but we have results_filing_dates_24mo. For 2025, Q2 was filed on Aug 13. So it's plausible that Q2 2026 will be filed around Aug 13, 2026, which is within 4 weeks from today July 20. That could be a catalyst. However, we need to check if there is a disclosure about the board meeting to approve results. There is no recent disclosure about a BOD meeting scheduled. But historically, it's consistent. So we can consider that as a potential catalyst? The instructions say: "Do not assert a specific dated catalyst ... unless it appears in a pack field or a filing_context excerpt." There is no explicit mention of an upcoming results filing date, but we have the pattern. However, we can't assert it as a specific catalyst. But we can note that the last results were in May, and the next may be outside horizon? Actually, if the pattern holds, it could be within horizon. But since it's not explicitly stated, we might not rely on it as a dated catalyst. The horizon ends Aug 17, so if they file on Aug 13-14, it's inside. But we don't have a confirmation. So we treat no specific dated catalyst. - Recent news: June 20, 2026: Amanat completed takeover of Cambridge Health Group, buying remaining 10.03% for AED105m. This gives full control. This is a positive, as it consolidates a key asset. Also, in July 6, CHG signed MoU with Middlesex University Dubai for healthcare education partnership. That could enhance the platform. - Sector news: Mostly banking, not directly relevant. One financial-services news about Revolut crypto license, not related. - Macro: US yields 4.57%, VIX 16.73, relatively stable. UAE macro news: Jaywan payment scheme launched, Emiratization surpassing targets, some geopolitical tensions (Houthi naval embargo) but unlikely to directly impact Amanat in short term. Now, for the SECTOR lens, we need to assess the company's fundamentals, growth, margins, leverage, dividend durability. Amanat has shown strong revenue growth (17.8% yoy, 13.9% CAGR), expanding margins, low debt, strong cash position, high and covered dividends. The recent full acquisition of CHG strengthens its healthcare platform. However, valuation is somewhat above peer median on PE, and analyst consensus is neutral/bearish in short term (TV recommend drift negative). Technicals show the stock has run up 15.99% in 3 months and may be overbought? RSI neutral, but CCI negative. The upcoming Q2 results could be a positive catalyst if they continue the trend, but that's not certain. Given the 4-week horizon, we need to decide stance: BUY, HOLD, SELL. Confidence bands: 90-100 if multiple aligned figures and a dated catalyst inside horizon. Here no dated catalyst, so max confidence 70-89 if several aligned figures. 50-69 if clear evidence with conflicts. Let's weigh. Positive factors: - Revenue growth accelerating: Q1 2026 rev yoy +24%, annual 2025 +17.8%. - Margins improving: net margin 22.3% in FY25, 24.2% in Q1 2026. - Strong balance sheet: cash 1450.4m, debt low (D/E 0.215). - Dividend yield 5.15%, well covered by earnings (payout 77.85% but FCF coverage strong per derived). Dividends seem durable. - Recent positive news: full ownership of CHG, partnership with Middlesex. - Outperformance vs market: +15.99% 3m vs DFMGI -1.19%. - Analyst target 1.445 implies 7.8% upside from 1.34. Negative factors: - Valuation somewhat high: PE 15.12 vs peer median 11.32 (64th percentile). - Technicals: TV recommend all negative, CCI -115, Stoch 31, Williams -63. Possibly overbought after strong run? But RSI 48 not overbought. - Consensus signal drift negative (-0.09, delta -0.267, -0.445), indicating recent analyst bearishness. - Next results could be within horizon, but no guarantee of positive surprise. If results disappoint, stock could sell off. - Geopolitical risks in region, though not directly impacting. I think the evidence is mixed: strong fundamental trends but valuation concerns and technical weakness. The upcoming Q2 results might be the swing factor, but we can't rely on it as a catalyst. Given the SECTOR lens, we care about fundamentals, and they are solid, but the short-term horizon might be influenced by technicals and market sentiment. Since the stock has rallied significantly, some consolidation or pullback is possible. However, the dividend yield and growth might provide support. We need to output HOLD if confidence below 40. I'd say confidence is around 50-69 because there are real conflicts. I'll lean towards HOLD with a target that maybe reflects the current price or slight upside. The analyst target is 1.445, but that's 12-month. For 4-week, we might derive a target based on evidence. If we think the price will move towards the ma50 or ma200? But since we are not using technicals predominantly, we might use a valuation approach or just set the target as the current price or slightly higher. The instructions: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean (a 12-month figure) as your own target." So w

We are the TECHNICAL lens. We must reason over the technical indicators: trend (MA50 vs MA200, price vs MA200), momentum, vol, drawdown/gap structure, relative strength vs DFMGI, and any corporate actions like ex-date drops. First, extract relevant technical fields: - spot: 1.34 - indicators.ma50: 1.3112 - indicators.ma200: 1.1924 - indicators.pct_vs_ma200: 12.3772 (price is 12.38% above MA200) - indicators.rsi14: 48.401 - indicators.realized_vol_annual_pct: 16.8981 - indicators.ret_1m_pct: 3.876 - indicators.ret_3m_pct: 15.9869 - indicators.ret_12m_pct: 31.0222 - indicators.rel_strength_3m_vs_dfmgi_pct: 10.8048 (outperforming DFMGI by ~10.8% over 3 months) - indicators.max_drawdown_1y_pct: -16.4286 - indicators.pct_off_20d_high: -4.2857 - indicators.atr14_pct_of_price: 2.2388 - indicators.largest_gap_3m_pct: 3.2787 - indicators.pct_no_trade_days_3m: 4.6875 - tv_technicals: tv_recommend_all: -0.1576 (bearish), tv_recommend_ma: -0.1333 (sell), tv_recommend_other: -0.1818 (sell). adx: 32.1821 (strong trend), cci20: -115.7556 (oversold), stoch_k: 31.1027 (near oversold), williams_r: -63.6364 (neutral-bearish). rel_volume: 1.2734. - dfmgi_context: dfmgi_ret_1m_pct: -5.958, dfmgi_ret_3m_pct: -1.1938, dfmgi_pct_vs_ma200: -3.5453. So DFMGI is below its MA200, while AMANAT is above. - corporate_actions.history: ex_date 2026-04-09 for 7% cash dividends. That was already past, so no upcoming ex-date in the horizon. So no mechanical drop to consider. Now, interpret for a 4-week horizon ending 2026-08-17. Trend: MA50 (1.3112) > MA200 (1.1924) --> golden cross territory, bullish. Price (1.34) is above both, so trend is up. Momentum: RSI14 at 48.4 is neutral, not overbought/oversold. CCI20 at -115.76 is oversold, suggesting possible bounce. Stoch K at 31.1, also low. But tv_recommend_all is bearish (-0.1576) and the moving averages recommendation is sell. That's conflicting. ADX at 32 suggests a strong trend, but direction? Not specified, but with price above MAs, likely uptrend. However, recent ret_1m_pct is modest +3.88%, ret_3m_pct +15.99%, so recent momentum is positive but maybe slowing. The pct_off_20d_high is -4.29%, indicating pullback from recent high. Volatility: realized vol 16.9% annualized, ATR14 2.24% of price, moderate. largest_gap_3m_pct 3.28% shows some gap risk. Relative strength vs DFMGI: AMANAT outperformed DFMGI by 10.8% over 3 months. DFMGI itself is down 1.2% over 3 months and below MA200. So AMANAT shows notable relative strength. Drawdown: max drawdown 1y -16.4%, which is significant. Overall technical picture: Trend is up (price > MA50 > MA200), but momentum oscillators are mixed (RSI neutral, CCI oversold, Stoch low) and tv_recommend is bearish. This suggests a potential consolidation or pullback within an uptrend. The recent 1-month return is positive but modest, and the stock is off its 20-day high. For a 4-week horizon, technicals might signal caution, but not a strong sell because the primary trend is bullish. The low RSI and oversold CCI could indicate a bounce, but the bearish tv signals weigh. Given the pack, there's no upcoming ex-date. The fundamentals are not our lens, but we note that the company has strong growth and low debt. But we only use technicals. Confidence assessment: We have some conflict: bullish trend (price above MAs) but bearish recommendations from tv_technicals. The evidence is mixed but not extremely one-sided. We have no dated catalyst in the technical lens. So confidence should be in the 50-69 range? Actually, the instructions: 70-89 = several aligned cited figures, no dated catalyst; 50-69 = clear evidence with real conflicts; 30-49 = mixed or one-sided evidence; 10-29 = thin/stale. Here, we have clear conflict: MA trend bullish vs TV bearish. So confidence likely 50-69. But we need at least two citations for non-HOLD stance. If we go HOLD, we can have lower confidence? Actually, we must output stance. HOLD if confidence below 40? The instruction says: "output HOLD below 40". So if we think confidence is 50-69, we can output BUY/SELL with that confidence, provided we have at least two citations. But if we think the conflict merits HOLD, we could output HOLD. Since the trend is bullish but oscillators are weak, a neutral stance (HOLD) might be appropriate for a 4-week horizon. Let's decide. Technicals alone: price above MA50 and MA200 suggests uptrend. But tv_recommend_all is negative. The relative strength vs DFMGI is positive. So we have both bullish and bearish signals. For a short horizon, the bearish oscillator signals might dominate. I'll lean towards HOLD because of the mixed signals. Confidence maybe 55 (clear evidence with real conflicts). Or could argue for a slight bullish tilt because trend is up and RS is strong, but TV says sell. I'll go with HOLD. We need to cite at least two fields for non-HOLD? If HOLD, we don't necessarily need two? The instructions: "non-HOLD stances need at least 2." So HOLD can have fewer citations. But better to include citations. We'll cite the technical fields. Pick citations: indicators.pct_vs_ma200 with value 12.3772, indicators.rsi14 with value 48.401, tv_technicals.tv_recommend_all with value -0.1576, etc. Also, point: one sentence citing a figure. risk: one line. Target: derive for 4-week horizon? The instructions say if you output a target, derive it from pack evidence for the 4-week horizon. Since we are HOLD, we might output null target. But we can output a target based on technicals? Typically, technical targets are not provided. So I'll set target to null. Confidence: Let's set to 55, as it's mixed with real conflicts. So output: { "citations": [ {"field": "indicators.pct_vs_ma200", "value": 12.3772}, {"field": "indicators.rsi14", "value": 48.401}, {"field": "tv_technicals.tv_recommend_all", "value": -0.1576} ], "point": "Price is 12.38% above the 200-day MA, confirming an uptrend, but RSI14 is neutral at 48.4 and the consensus technical rating is bearish at -0.16.", "risk": "Downside risk from the stock already being 4.3% off its 20-day high amid a strong ADX trend of 32.2.", "stance": "HOLD", "confidence": 55, "target": null } We need exactly the keys in order: citations, point, risk, stance, confidence, target. And JSON only. So that's it.

We are asked to produce a valuation lens rating for AMANAT. We need to consider multiples vs fair value, dividend support, analyst consensus including drift. The horizon is 4 weeks (ending 2026-08-17). We must cite exact figures from the pack. No invented catalysts. We need to output a JSON with citations, point, risk, stance, confidence, target. First, let's extract relevant data for the valuation lens: - Fundamentals: pe_ttm = 15.1242, pb = 1.1691, ps = 3.4225, dividend_yield = 5.1471, payout_ratio = 77.85. - Peer context: median_pe_ttm = 11.32, median_pb = 1.35, median_div_yield = 4.55. So Amanat trades at a premium on P/E (15.12 vs 11.32 median, pe_percentile 64) but at a discount on P/B (1.17 vs 1.35). Dividend yield is above median (5.15% vs 4.55%, div_yield_percentile 67). - Analyst: n=2, rec=none, target_mean=1.445, implied_upside_pct=7.8358. But note: analyst consensus is thin (only 2 analysts) and rec is "none", meaning no clear consensus rating. Also, target_mean_delta_10d_pct = 0.0, so no drift in target price over last 10 days. However, consensus_signal_drift shows tv_recommend_all = -0.0909 (slightly bearish), tv_recommend_delta_5d = -0.267, tv_recommend_delta_10d = -0.445, indicating downward drift in technical recommendations. That may factor into analyst sentiment? But consensus_signal_drift is for technicals? Actually, the field consensus_signal_drift includes tv_recommend_all, tv_recommend_delta, etc. So it's a blend of analyst and technical? It says "consensus_signal_drift", likely from TradingView. The forward_pe is 22.3333, which is high relative to trailing PE of 15.12, suggesting expected earnings decline or slow growth? Actually forward PE higher than trailing could be because of high growth expectations? Wait, trailing PE is 15.12, forward PE 22.33, so forward earnings are expected to be lower? Typically forward PE = price / expected earnings. If forward PE > trailing PE, then expected earnings are lower than trailing, unless price is expected to change. That might be a red flag. - Dividend support: financial_statements.derived.div_paid_to_fcf = 0.2. That's low, meaning dividends are only 20% of free cash flow, so well covered. fcf_margin_pct = 9.7. That's decent. In annual statements: dividends_paid in 2025 was -18.5, fcf was 90.8, so div/fcf = 18.5/90.8 ≈ 0.2037, matches 0.2. In 2024, div_paid -15.8, fcf 79.3, ratio ~0.2. So dividend payments have been sustainable. The latest corporate action: Cash Dividends 7% for 2026 ex-date 2026-04-09. So a decent dividend. - Valuation: Given PE of 15.12 vs peer median 11.32, the stock looks expensive on earnings. But ROE is 8.1%, which is modest. PB of 1.17 is slightly below peer median 1.35, so maybe book value is more reasonable. But overall, valuation seems mixed. - Recent news: Amanat completed acquisition of remaining 10.03% of Cambridge Health Group for AED105 million, giving full control. That could be a catalyst, but it's already announced and completed. There is a strategic partnership with Middlesex University Dubai on July 6. No specific dated catalyst for the next 4 weeks that would move the stock, except perhaps market reaction to these completed deals? No upcoming results filing? Last results was Q1 2026 on May 14. Next results likely Q2/H1 2026, but that might be after the horizon? Horizon ends Aug 17, Q2 results typically in Aug? For 2025, Q2 results were filed Aug 13 (2025-08-13). So possibly Q2 2026 results could be around mid-August, which might fall within the horizon? The results filing dates: 2025-08-13, so next one could be similar. But we don't have a confirmation. Not a clear dated catalyst. - Technicals: Indicators ret_1m_pct = 3.876, ret_3m_pct = 15.99, stock up nicely. But RSI14 = 48.4, neutral. Price vs MA200 = +12.38%, so above long-term average but not overbought. Max drawdown 1y = -16.4%. Volatility 16.9% annual. - Analyst consensus drift: tv_recommend_delta_10d = -0.445, strong negative drift. target_mean_delta_10d_pct = 0.0, so no change in target. Forward PE 22.33, target_dispersion 0.13, low dispersion. tv_recommend_all = -0.0909. We need to form a stance for the 4-week horizon. As a valuation lens, we'd look at multiples vs fair value. If the stock is overvalued relative to peers, we might be SELL. But it's not extremely overvalued. However, with a thin analyst following and neutral to negative technical sentiment, maybe we lean HOLD. The dividend yield is supportive, but that's for longer term. For 4 weeks, valuation multiples alone might not drive a big move unless there's a catalyst. So likely HOLD. Confidence: We have mixed signals: PE above median, PB below, dividend above, and low analyst conviction. No clear catalyst. So confidence in the 50-69 range? Or lower? The instructions: "50-69 = clear evidence with real conflicts". Here we have real conflicts: valuation mixed, analyst drift negative but no clear rating. So maybe 55. But we need to cite exact figures. Point: Summarize valuation vs peers, dividend support. e.g., "Trades at PE 15.1x (peer median 11.3x) but PB 1.17x (peer median 1.35x), with dividend yield 5.15% covered by FCF (div/FCF 0.20), yet forward PE spike to 22.3x and analyst consensus turning cautious (TV rec delta -0.445) signal limited 4-week upside." Risk: e.g., "Downside risk if market reprices toward peer median PE, though dividend and low leverage provide support." Stance: HOLD, confidence maybe 55? But target: for HOLD, we might output null or a target near spot? The instructions: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean (a 12-month figure) as your own target." So we could derive a target. For HOLD, maybe no target, but we can give null. Usually HOLD means no strong directional call, so target null. But we could also output a target based on e.g., a blend of peer median PE and PB to get a fair value and then discount for no catalyst? That might be too speculative. I'll set target as null. Confidence: I'll set 55 as there are clear conflicts: PE premium vs PB discount, high dividend vs forward PE spike, analyst drift negative but no rating change. And no dated catalyst. citations: need at least two for non-HOLD, but this is HOLD? Wait, "non-HOLD stances need at least 2." So HOLD can have less? But we'll still provide a few. We'll cite: fundamentals.pe_ttm=15.1242, peer_context.median_pe_ttm=11.32, fundamentals.pb=1.1691, peer_context.median_pb=1.35, fundamentals.dividend_yield=5.1471, financial_statements.derived.div_paid_to_fcf=0.2, consensus_signal_drift.tv_recommend_delta_10d=-0.445, consensus_signal_drift.forward_pe=22.3333. We'll pick a couple. The point will mention them. Let's structure the JSON. { "citations": [ {"field": "fundamentals.pe_ttm", "value": 15.1242}, {"field": "peer_context.median_pe_ttm", "value": 11.32}, {"field": "fundamentals.pb", "value": 1.1691}, {"field": "peer_context.median_pb", "value": 1.35}, {"field": "fundamentals.dividend_yield", "value": 5.1471}, {"field": "financial_statements.derived.div_paid_to_fcf", "value": 0.2}, {"field": "consensus_signal_drift.tv_recommend_delta_10d", "value": -0.445}, {"field": "consensus_signal_drift.forward_pe", "value": 22.3333} ], "point": "AMANAT trades at a premium PE of 15.1x vs peer median 11.3x but a discount PB of 1.17x vs 1.35x, with a well-covered 5.15% yield (div/FCF 0.20), yet forward PE spikes to 22.3x and analyst consensus drift is negative (10d TV rec delta -0.445), creating valuation ambiguity for the 4-week horizon.", "risk": "If the market reprices toward peer median PE, downside could emerge, though dividend support and low leverage (debt/equity 0.21) cushion the risk.", "stance": "HOLD", "confidence": 55, "target": null } Confidence 55 fits the "clear evidence with real conflicts" range. No dated catalyst inside the horizon, so not above 70. So it's good.